Arcus Biosciences, Inc. Earnings Dividend

Arcus Biosciences, Inc.’s revenue fell -39.29% since last year same period to $17Mn in the Q1 2026. On a quarterly growth basis, Arcus Biosciences, Inc. has generated -48.48% fall in its revenue since last 3-months.

Arcus Biosciences, Inc.’s net profit fell -14.29% since last year same period to $-128Mn in the Q1 2026. On a quarterly growth basis, Arcus Biosciences, Inc. has generated -30.61% fall in its net profits since last 3-months.

Arcus Biosciences, Inc.’s net profit margin fell -88.24% since last year same period to -752.94% in the Q1 2026. On a quarterly growth basis, Arcus Biosciences, Inc. has generated -153.54% fall in its net profit margins since last 3-months.

Arcus Biosciences, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.81 - a 2.41% jump from last quarter’s estimates.

Arcus Biosciences, Inc.’s earning per share (EPS) estimates for the current year stand at -0.81.

Arcus Biosciences, Inc.’s earning per share (EPS) jumped 10.53% since last year same period to -1.02 in the Q1 2026. This indicates that the Arcus Biosciences, Inc. has generated 10.53% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Arcus Biosciences, Inc.’s return on assets (ROA) stands at -0.23.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Arcus Biosciences, Inc.’s return on equity (ROE) stands at -0.7.